11 COMMERCE DRIVE, CRANFORD, NJ
Market cap: $8.6M (2/12/2026)
Price: $0.77
Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Corporate Overview
Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws, Shareholder votes
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement